Positive pivotal Lilly data set stage for Taltz approval in non-radiographic axial spondyloarthritis
Having secured approval for psoriatic arthritis and plaque psoriasis, Lilly is plotting to get its monoclonal antibody Taltz across the finish line for a form of inflammatory arthritis in which there is no visible evidence of damage on X-rays — non-radiographic axial spondyloarthritis (nr-AxSpA). On Monday, the drugmaker reported the treatment had cleared a late-stage study, setting the stage for a regulatory submission later this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.